Physician profile
Daniel Gerber
NPI 1831694694
$2,356.28
in general payments reported to CMS, 2019-2025
25 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $170 · 2024: $520 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.10 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $658.84 | 2022-2025 | Ams 800 Artificial Urinary Sphincter, Ams 700, Lithovue |
| Sumitomo Pharma America, INC. | $421.06 | 2024-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $259.48 | 2024-2025 | |
| Intuitive Surgical, INC. | $150.69 | 2023-2024 | |
| Astellas Pharma US INC | $124.86 | 2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $110.24 | 2024-2025 | |
| Olympus America INC. | $76.39 | 2024-2025 | Soltive, Itind System |
| Progenics Pharmaceuticals, INC. | $70.21 | 2025 | |
| Urogen Pharma, INC. | $69.60 | 2025 | |
| Merck Sharp & Dohme LLC | $53.07 | 2024-2025 | Keytruda, Lynparza |
| Endo USA, INC. | $50.61 | 2025 | Xiaflex, Aveed |
| Teleflex LLC | $29.46 | 2025 | Urolift |
| Astrazeneca Pharmaceuticals Lp | $28.29 | 2025 | Lynparza |
| Immunitybio, INC. | $24.86 | 2025 | |
| Tolmar, INC. | $24.64 | 2025 | Eligard |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $24.16 | 2025 | Trelstar |
| Janssen Biotech, INC. | $24.08 | 2025 | Erleada |
| Abbvie INC. | $22.80 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.97 | 2025 | Adstiladrin |
| Azurity Pharmaceuticals, INC. | $20.99 | 2025 | Azmiro |
| Antares Pharma, INC. | $19.73 | 2025 | Xyosted |
| Accord Healthcare, INC. | $18.28 | 2025 | |
| Procept Biorobotics Corporation | $18.23 | 2024 | Aquabeam System |
| Laborie Medical Technologies Corp. | $18.10 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Valencia Technologies Corporation | $15.64 | 2025 | Ecoin Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.